Bertini M, Marinone C, Giovarelli M, Comoglio P M
G Batteriol Virol Immunol. 1977 Jul-Dec;70(7-12):144-56.
The MOPC-460 plasma cell tumor possesses tumor specific antigens. It nevertheless grows and kills its syngeneic host. The possible impairment of immune responsiveness in tumor bearing mice was investigated by measuring their ability to mount a humoral immune response against foreign antigens, such as sheep red blood cells or bacteriophage T4. No significant decrease in the response to either antigen was found until the tumor mass exceeded 10-15% of the host's body weight. Moreover, circulating anti-tumor antibodies were detected in the serum throughout the initial period of tumor growth. The possible interference of these antibodies with cell-mediated defence mechanism was ruled out by experiments where the humoral response was selectively suppressed from birth by repeated administrations of anti-immunoglobulin heavy chain antiserum. In a "suppressed" mice, tumors took, grew and developed more rapidly than in controls. It is concluded that, at least in the model studied, the humoral immune response operates as a defence mechanism against expansion of the tumor clone.
MOPC - 460浆细胞瘤具有肿瘤特异性抗原。然而，它仍会生长并杀死同基因宿主。通过测量荷瘤小鼠针对外来抗原（如绵羊红细胞或噬菌体T4）产生体液免疫反应的能力，研究了荷瘤小鼠免疫反应可能受到的损害。在肿瘤质量超过宿主体重的10 - 15%之前，未发现对任何一种抗原的反应有显著下降。此外，在肿瘤生长的最初阶段，血清中始终能检测到循环抗肿瘤抗体。通过反复给予抗免疫球蛋白重链抗血清从出生起选择性抑制体液反应的实验，排除了这些抗体对细胞介导防御机制的可能干扰。在“抑制”小鼠中，肿瘤的接种、生长和发展比对照组更快。得出的结论是，至少在所研究的模型中，体液免疫反应作为一种防御机制对抗肿瘤克隆的扩张。
